Investigational New Drugs

, Volume 28, Issue 3, pp 234–241 | Cite as

FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer

  • Feng Wang
  • Scharri J. Ezell
  • Yong Zhang
  • Wei Wang
  • Elizabeth R. Rayburn
  • Dwayaja H. Nadkarni
  • Srinivasan Murugesan
  • Sadanandan E. Velu
  • Ruiwen Zhang


We recently synthesized a series of novel makaluvamine compounds, and found that the most potent was FBA-TPQ. The effects of FBA-TPQ on human (LNCaP and PC3) and murine (TRAMP C1) prostate cancer cells were evaluated. Potential mechanisms of action of the compound were also determined. FBA-TPQ exhibited dose-dependent cytotoxicity in the low micromolar range, inhibited proliferation, caused cell cycle arrest, and induced apoptosis in prostate cancer cell lines. The compound also decreased the expression of the androgen receptor and PSA. The results presented herein support the further development of FBA-TPQ as a novel agent for prostate cancer.


Makaluvamine Prostate cancer Chemotherapy Cell cycle Apoptosis 



This work was supported by NIH grants R01 CA112029 and R01 CA121211. E. Rayburn was supported by a DoD grant (W81XWH-06-1-0063) and a T32 fellowship from the NIH/UAB Gene Therapy Center (CA075930). The apoptosis analyses were performed by the Flow Cytometry Core of the Arthritis and Musculoskeletal Center, which is supported in part by an NIH grant (P60 AR20614). S. E. Velu was supported by a translational research grant from the UAB Council of University-Wide Interdisciplinary Research Centers.


  1. 1.
    American Cancer Society, Inc. Leading Sites of New Cancer Cases and Deaths-2007 Estimates. Surveillance Research. 2007. Available online. Accessed 9 December 2008
  2. 2.
    Quinn DI, Henshall SM, Sutherland RL (2005) Molecular markers of prostate cancer outcome. Eur J Cancer 41:858–887 doi: 10.1016/j.ejca.2004.12.035 CrossRefPubMedGoogle Scholar
  3. 3.
    Petrylak DP (2005) The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65:3–7 doi: 10.1016/j.urology.2005.03.053 CrossRefPubMedGoogle Scholar
  4. 4.
    Tammela T (2004) Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 92:287–295 doi: 10.1016/j.jsbmb.2004.10.005 CrossRefPubMedGoogle Scholar
  5. 5.
    Haefner B (2003) Drugs from the deep: marine natural products as drug candidates. Drug Discov Today 8:536–544 doi: 10.1016/S1359-6446(03)02713-2 CrossRefPubMedGoogle Scholar
  6. 6.
    Blunt JW, Copp BR, Munro MH et al (2006) Marine natural compounds. Nat Prod Rep 23:26–78 doi: 10.1039/b502792f CrossRefPubMedGoogle Scholar
  7. 7.
    Marris E (2006) Marine natural products: drugs from the deep. Nature 443:904–905 doi: 10.1038/443904a CrossRefPubMedGoogle Scholar
  8. 8.
    Schwartsmann G, Brondani da Rocha A, Berlinck RG, Jimeno J (2001) Marine organisms as a source of new anticancer agents. Lancet Oncol 2:221–225 doi: 10.1016/S1470-2045(00)00292-8 CrossRefPubMedGoogle Scholar
  9. 9.
    Dijoux MG, Gamble WR, Hallock YF, Cardellina JH, van Soest R, Boyd MR (1999) A new discorhabdin from two sponge genera. J Nat Prod 62:636–637 doi: 10.1021/np980465r CrossRefPubMedGoogle Scholar
  10. 10.
    Carney JR, Scheuer PJ, Kelly-Borges M (1993) A new bastadin from the sponge Psammaplysilla purpurea. J Nat Prod 56:153–157 doi: 10.1021/np50091a025 CrossRefPubMedGoogle Scholar
  11. 11.
    Casapullo A, Cutignano A, Bruno I et al (2001) Makaluvamine P, a new cytotoxic pyrroloiminoquinone from Zyzzya cf. fuliginosa. J Nat Prod 64:1354–1356 doi: 10.1021/np010053+ CrossRefPubMedGoogle Scholar
  12. 12.
    Sipkema D, Franssen MC, Osinga R, Tramper J, Wijffels RH (2005) Marine sponges as pharmacy. Mar Biotechnol 7:142–162 doi: 10.1007/s10126-004-0405-5 CrossRefPubMedGoogle Scholar
  13. 13.
    Shinkre BA, Raisch KP, Fan L, Velu SE (2007) Analogs of the marine alkaloid makaluvamines: synthesis, topoisomerase II inhibition, and anticancer activity. Bioorg Med Chem Lett 17:2890–2893 doi: 10.1016/j.bmcl.2007.02.065 CrossRefPubMedGoogle Scholar
  14. 14.
    Velu SE, Pillai SK, Lakshmikantham MV, Billimoria AD, Culpepper JS, Cava MP (1995) Efficient syntheses of the marine alkaloids makaluvamine D and discorhabdin C: the 4,6,7-trimethoxyindole approach. J Org Chem 60:1800–1805 doi: 10.1021/jo00111a043 CrossRefGoogle Scholar
  15. 15.
    Shinkre BA, Raisch KP, Fan L, Velu SE (2008) Synthesis and antiproliferative activity of benzyl and phenethyl analogs of makaluvamines. Bioorg Med Chem 16:2541–2549CrossRefPubMedGoogle Scholar
  16. 16.
    Jiang C, Lee HJ, Li GX et al (2006) Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res 66:453–463 doi: 10.1158/0008-5472.CAN-05-1865 CrossRefPubMedGoogle Scholar
  17. 17.
    Cho SD, Jiang C, Malewicz B et al (2004) Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 3:605–611PubMedGoogle Scholar
  18. 18.
    Barrows LR, Radisky DC, Copp BR et al (1993) Makaluvamines, marine natural products, are active anti-cancer agents and DNA topo II inhibitors. Anticancer Drug Des 8:333–347PubMedGoogle Scholar
  19. 19.
    Newman DJ, Cragg GM (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 67:1216–1238 doi: 10.1021/np040031y CrossRefPubMedGoogle Scholar
  20. 20.
    Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH (2005) Marine natural products as anticancer drugs. Mol Cancer Ther 4:333–342PubMedGoogle Scholar
  21. 21.
    Schlomm T, Iwers L, Kirstein P et al (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21:1371–1378 doi: 10.1038/modpathol.2008.104 CrossRefPubMedGoogle Scholar
  22. 22.
    Schafer KA (1998) The cell cycle: a review. Vet Pathol 35:461–478CrossRefPubMedGoogle Scholar
  23. 23.
    Seville LL, Shah N, Westwell AD, Chan WC (2005) Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets 5:159–170 doi: 10.2174/1568009053765816 CrossRefPubMedGoogle Scholar
  24. 24.
    Zinkel S, Gross A, Yang E (2006) BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13:1351–1359 doi: 10.1038/sj.cdd.4401987 CrossRefPubMedGoogle Scholar
  25. 25.
    Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R (2003) Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 1002:217–235 doi: 10.1196/annals.1281.025 CrossRefPubMedGoogle Scholar
  26. 26.
    Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R (2005) Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 24:7238–7247 doi: 10.1038/sj.onc.1208814 CrossRefPubMedGoogle Scholar
  27. 27.
    Zhang Z, Zhang R (2005) p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 5:9–20 doi: 10.2174/1568009053332618 CrossRefPubMedGoogle Scholar
  28. 28.
    Gaughan L, Logan IR, Neal DE, Robson CN (2005) Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 33:13–26 doi: 10.1093/nar/gki141 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Feng Wang
    • 1
  • Scharri J. Ezell
    • 1
  • Yong Zhang
    • 4
  • Wei Wang
    • 1
  • Elizabeth R. Rayburn
    • 1
    • 2
  • Dwayaja H. Nadkarni
    • 3
  • Srinivasan Murugesan
    • 3
  • Sadanandan E. Velu
    • 3
  • Ruiwen Zhang
    • 1
    • 2
  1. 1.Division of Clinical Pharmacology, Department of Pharmacology and ToxicologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Gene Therapy CenterUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.Department of ChemistryUniversity of Alabama at BirminghamBirminghamUSA
  4. 4.Hormel InstituteUniversity of MinnesotaAustinUSA

Personalised recommendations